Publication

Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension

Heesen, WF., Beltman, FW., Smith, AJ., May, JF., de Graeff, PA., Muntinga, JHJ., Havinga, TK., Schuurman, FH., van der Veur, E., Meyboom-de Jong, B. & Lie, KI., May-2001, In : Journal of Cardiovascular Pharmacology. 37, 5, p. 512-521 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Heesen, WF., Beltman, FW., Smith, AJ., May, JF., de Graeff, PA., Muntinga, JHJ., Havinga, TK., Schuurman, FH., van der Veur, E., Meyboom-de Jong, B., & Lie, KI. (2001). Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. Journal of Cardiovascular Pharmacology, 37(5), 512-521.

Author

Heesen, WF ; Beltman, FW ; Smith, AJ ; May, JF ; de Graeff, PA ; Muntinga, JHJ ; Havinga, TK ; Schuurman, FH ; van der Veur, E ; Meyboom-de Jong, B ; Lie, KI. / Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. In: Journal of Cardiovascular Pharmacology. 2001 ; Vol. 37, No. 5. pp. 512-521.

Harvard

Heesen, WF, Beltman, FW, Smith, AJ, May, JF, de Graeff, PA, Muntinga, JHJ, Havinga, TK, Schuurman, FH, van der Veur, E, Meyboom-de Jong, B & Lie, KI 2001, 'Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension', Journal of Cardiovascular Pharmacology, vol. 37, no. 5, pp. 512-521.

Standard

Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. / Heesen, WF; Beltman, FW; Smith, AJ; May, JF; de Graeff, PA; Muntinga, JHJ; Havinga, TK; Schuurman, FH; van der Veur, E; Meyboom-de Jong, B; Lie, KI.

In: Journal of Cardiovascular Pharmacology, Vol. 37, No. 5, 05.2001, p. 512-521.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Heesen WF, Beltman FW, Smith AJ, May JF, de Graeff PA, Muntinga JHJ et al. Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. Journal of Cardiovascular Pharmacology. 2001 May;37(5):512-521.


BibTeX

@article{ccbd9bc785fb433fa6d1b8bbd17cfd7b,
title = "Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension",
abstract = "The purpose of this study was to evaluate in a prospective, double-blind, placebo-controlled study the effect of long-term (2-year) lisinopril treatment on cardiovascular end-organ damage in patients with previously untreated isolated systolic hypertension (ISH). All patients with ISH were derived from a population screening program. End-organ damage measurements, done initially and after 6 and 24 months of treatment, included measurements of aortic distensibility and echocardiographic left ventricular mass index (LVMI) and diastolic function. Blood pressure was measured by office and ambulatory measurements. Of the 97 subjects with ISH selected from the screening, 62 (30 lisinopril) completed the study according to protocol. Office blood pressure decreased in both groups, but ambulatory results significantly decreased with lisinopril-treatment only. Aortic distensibility increased significantly with lisinopril, as opposed to a decrease in placebo-treated subjects. The main effect of increased distensibility occurred between 6 and 24 months, whereas ambulatory blood pressure changed mainly in the first 6 months of treatment. LVMI decreased in both treatment groups, with a significantly higher reduction in lisinopril-treated subjects. Left ventricular diastolic function showed no significant changes in either group. The vascular pathophysiologic alterations of ISH-a decreased aortic distensibility-can be improved with long-term lisinopril treatment, whereas values deteriorate further in placebo-treated subjects. These results, in one of the first studies including subjects with previously untreated ISH only, indicate that lisinopril treatment might favorably influence the cardiovascular risk of ISH.",
keywords = "hypertension, systolic, drug treatment, echocardiography, hypertrophy, vascular, pathophysiology, LEFT-VENTRICULAR MASS, ANTIHYPERTENSIVE TREATMENT, CARDIAC-HYPERTROPHY, MILD HYPERTENSION, ANATOMIC VALIDATION, WALL HYPERTROPHY, ELDERLY PATIENTS, OLDER PATIENTS, REGRESSION, PRESSURE",
author = "WF Heesen and FW Beltman and AJ Smith and JF May and {de Graeff}, PA and JHJ Muntinga and TK Havinga and FH Schuurman and {van der Veur}, E and {Meyboom-de Jong}, B and KI Lie",
year = "2001",
month = may,
language = "English",
volume = "37",
pages = "512--521",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
number = "5",

}

RIS

TY - JOUR

T1 - Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension

AU - Heesen, WF

AU - Beltman, FW

AU - Smith, AJ

AU - May, JF

AU - de Graeff, PA

AU - Muntinga, JHJ

AU - Havinga, TK

AU - Schuurman, FH

AU - van der Veur, E

AU - Meyboom-de Jong, B

AU - Lie, KI

PY - 2001/5

Y1 - 2001/5

N2 - The purpose of this study was to evaluate in a prospective, double-blind, placebo-controlled study the effect of long-term (2-year) lisinopril treatment on cardiovascular end-organ damage in patients with previously untreated isolated systolic hypertension (ISH). All patients with ISH were derived from a population screening program. End-organ damage measurements, done initially and after 6 and 24 months of treatment, included measurements of aortic distensibility and echocardiographic left ventricular mass index (LVMI) and diastolic function. Blood pressure was measured by office and ambulatory measurements. Of the 97 subjects with ISH selected from the screening, 62 (30 lisinopril) completed the study according to protocol. Office blood pressure decreased in both groups, but ambulatory results significantly decreased with lisinopril-treatment only. Aortic distensibility increased significantly with lisinopril, as opposed to a decrease in placebo-treated subjects. The main effect of increased distensibility occurred between 6 and 24 months, whereas ambulatory blood pressure changed mainly in the first 6 months of treatment. LVMI decreased in both treatment groups, with a significantly higher reduction in lisinopril-treated subjects. Left ventricular diastolic function showed no significant changes in either group. The vascular pathophysiologic alterations of ISH-a decreased aortic distensibility-can be improved with long-term lisinopril treatment, whereas values deteriorate further in placebo-treated subjects. These results, in one of the first studies including subjects with previously untreated ISH only, indicate that lisinopril treatment might favorably influence the cardiovascular risk of ISH.

AB - The purpose of this study was to evaluate in a prospective, double-blind, placebo-controlled study the effect of long-term (2-year) lisinopril treatment on cardiovascular end-organ damage in patients with previously untreated isolated systolic hypertension (ISH). All patients with ISH were derived from a population screening program. End-organ damage measurements, done initially and after 6 and 24 months of treatment, included measurements of aortic distensibility and echocardiographic left ventricular mass index (LVMI) and diastolic function. Blood pressure was measured by office and ambulatory measurements. Of the 97 subjects with ISH selected from the screening, 62 (30 lisinopril) completed the study according to protocol. Office blood pressure decreased in both groups, but ambulatory results significantly decreased with lisinopril-treatment only. Aortic distensibility increased significantly with lisinopril, as opposed to a decrease in placebo-treated subjects. The main effect of increased distensibility occurred between 6 and 24 months, whereas ambulatory blood pressure changed mainly in the first 6 months of treatment. LVMI decreased in both treatment groups, with a significantly higher reduction in lisinopril-treated subjects. Left ventricular diastolic function showed no significant changes in either group. The vascular pathophysiologic alterations of ISH-a decreased aortic distensibility-can be improved with long-term lisinopril treatment, whereas values deteriorate further in placebo-treated subjects. These results, in one of the first studies including subjects with previously untreated ISH only, indicate that lisinopril treatment might favorably influence the cardiovascular risk of ISH.

KW - hypertension

KW - systolic

KW - drug treatment

KW - echocardiography

KW - hypertrophy

KW - vascular

KW - pathophysiology

KW - LEFT-VENTRICULAR MASS

KW - ANTIHYPERTENSIVE TREATMENT

KW - CARDIAC-HYPERTROPHY

KW - MILD HYPERTENSION

KW - ANATOMIC VALIDATION

KW - WALL HYPERTROPHY

KW - ELDERLY PATIENTS

KW - OLDER PATIENTS

KW - REGRESSION

KW - PRESSURE

M3 - Article

VL - 37

SP - 512

EP - 521

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -

ID: 3934939